The DAWNA‐1 trial explored the efficacy and safety of dalpiciclib plus fulvestrant in patients with HR‐positive, HER2‐negative advanced breast cancer whose disease had progressed after prior endocrine therapy. The gene discussed is ERBB2; the disease is breast carcinoma.